| Literature DB >> 29948352 |
Sibel Zehra Aydin1, Orhan Kucuksahin2, Levent Kilic3, Atalay Dogru4, Ozun Bayindir5, Cem Ozisler6, Ahmet Omma7, Emine Figen Tarhan8, Abdulsamet Erden9, Gezmis Kimyon10, Meryem Can11, Ediz Dalkilic12, Sule Yavuz11, Sibel Bakirci Ureyen13, Esen Kasapoglu Gunal14, Fatıma Arslan Alhussain15, Lutfi Akyol16, Ayse Balkarli17, Sema Yilmaz18, Muhammet Cinar19, Muge Tufan Aydin20, Dilek Solmaz21, Ridvan Mercan22, Sukran Erten2, Umut Kalyoncu23.
Abstract
Psoriatic arthritis (PsA) may affect different joints, including the spine. The prevalence of spinal involvement is variable depending on the definition and a subset of patients have been identified in cohorts that do not have clinical features of axial disease and yet have imaging findings. Still, there is not a consensus on how and when to screen axial disease. In this study, we aimed to investigate factors associated with being underdiagnosed for axial psoriatic arthritis (axPsA) and its impacts on outcomes. Disease features and outcomes of axPsA according to the physician (n = 415) were compared with patients with imaging findings only (sacroiliitis fulfilling the modified New York criteria, n = 112), using data from a real-life PsA registry. Patients with imaging findings only were more frequently women (83/220 (37.7%) vs 29/122 (23.8%); p = 0.008). This group also had higher peripheral disease activity (imaging only vs clinical AxPsA: mean (SD) tender joint count 5.3 (6.1) vs 3.3 (4.7), swollen joint count 1.9 (2.9) vs 1.2 (2.4); p < 0.001 for both comparisons) and was less often treated using TNF inhibitors (16.1 vs 38.2%; p < 0.001) than patients who were classified as axPsA. Patient-reported outcomes were similar in both groups. PsA patients, especially women with more severe peripheral disease, have a higher risk of being underdiagnosed for axPsA. The severity of peripheral symptoms may be a risk factor to mask the spinal features of PsA.Entities:
Keywords: Axial disease; Psoriatic arthritis; Radiography
Mesh:
Year: 2018 PMID: 29948352 DOI: 10.1007/s10067-018-4173-4
Source DB: PubMed Journal: Clin Rheumatol ISSN: 0770-3198 Impact factor: 2.980